Filing Flows › Comparisons › ACRS vs VTGN
Aclaris Therapeutics vs Vistagen Therapeutics: ACRS and VTGN compared
Aclaris Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q3 2026) against $1.5M for Vistagen Therapeutics (Q1 FY27). Vistagen Therapeutics is growing faster (+505% against -55% a year earlier).
Where the money goes: ACRS and VTGN
Aclaris Therapeutics (ACRS) · Q3 2026
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
Vistagen Therapeutics (VTGN) · Q1 FY27
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Aclaris Therapeutics (ACRS) | Vistagen Therapeutics (VTGN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY27 |
| Revenue | $1.5M | $1.5M |
| Revenue growth, Y/Y | -55% | +505% |
| Operating margin | n/m | -904.3% |
| Net earnings | −$18.5M | −$13.0M |
| Net margin | — | -882.8% |
| Operating cash flow | −$24.1M | −$14.7M |
Where the revenue comes from
Aclaris Therapeutics
- Licensing: $1.2M (80%)
- Contract research: $300K (20%)
Questions
Which is bigger, Aclaris Therapeutics or Vistagen Therapeutics?
Aclaris Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q3 2026) against $1.5M for Vistagen Therapeutics (Q1 FY27).
Is Aclaris Therapeutics or Vistagen Therapeutics growing faster?
Vistagen Therapeutics is growing faster (+505% against -55% a year earlier).
More: Aclaris Therapeutics earnings · how Aclaris Therapeutics makes money · Vistagen Therapeutics earnings · how Vistagen Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.